Defining Disease Flare and Activity in MCTD
Unfortunately, there are no established, validated criteria for defining disease flares or determining active disease specifically in MCTD. The available guidelines focus primarily on screening and monitoring for interstitial lung disease (ILD) rather than defining overall disease activity or flare criteria.
Current Approach to Assessing MCTD Activity
Given the absence of MCTD-specific activity criteria, clinicians must assess disease activity by evaluating individual organ system involvement:
Clinical Manifestations to Monitor
Active disease should be suspected when patients develop:
- Pulmonary involvement: New or worsening dyspnea, declining pulmonary function tests (PFTs), progression on HRCT imaging 1
- Musculoskeletal features: Active inflammatory arthritis, myositis with elevated muscle enzymes, new muscle weakness
- Skin manifestations: Worsening Raynaud's phenomenon, new puffy hands, sclerodactyly progression
- Esophageal dysfunction: New or worsening dysphagia, esophageal dysmotility 2
- Systemic symptoms: Fatigue, fever, weight loss
Objective Measures for Disease Monitoring
For pulmonary disease activity (the most critical prognostic factor):
- PFTs (spirometry and DLCO): Declining FVC or DLCO indicates progression 1, 3
- HRCT chest: New ground-glass opacities or increasing fibrosis 1
- Frequency: Patients with SSc phenotype require PFTs every 6 months and HRCT annually for first 3-4 years; others need annual PFTs with HRCT if abnormalities detected 1
Laboratory markers:
- Elevated inflammatory markers (ESR, CRP) when previously normal
- Rising anti-RNP antibody titers (high titers predict ILD progression) 1
- New autoantibodies (anti-Smith, anti-Ro-52) 1
Borrowed Activity Indices
In clinical practice and research, MCTD activity has been assessed using:
- SLEDAI-2K (SLE Disease Activity Index): Scores >0 suggest active disease 4
- EUSTAR activity index: Scores ≥2.5 indicate active disease 4
Important caveat: These indices were developed for other diseases (SLE and SSc) and are not validated for MCTD, but provide some framework for assessment 4.
Defining Remission (Inverse of Active Disease)
Based on research data, remission in MCTD can be defined as:
- SLEDAI-2K score of 0 AND
- EUSTAR activity index <2.5 4
Only 13% of patients achieve sustained remission over long-term follow-up, though most patients have relatively low disease activity scores suggesting milder disease course 4.
Clinical Pitfalls
Do not confuse stable disease with remission: Over 90% of MCTD patients have EUSTAR scores <2.5, but this reflects the generally milder course rather than true remission 4.
Watch for evolution to differentiated CTD: Approximately 25-26% of patients progress to systemic sclerosis (15.8%) or SLE (10.6%) over median 5 years, which changes the disease activity assessment approach 5.
Risk factors for progression (suggesting more active/aggressive disease):
Practical Algorithm for Determining Active Disease
- Assess new or worsening symptoms in any organ system (pulmonary, musculoskeletal, cutaneous, esophageal)
- Check objective measures: PFTs if respiratory symptoms, muscle enzymes if weakness, inflammatory markers
- Obtain HRCT if declining PFTs or new respiratory symptoms
- Consider disease flare if: New organ involvement, declining objective measures, or rising inflammatory markers in previously controlled patient
- For treatment decisions: Short-term glucocorticoids may be used for disease flares or as bridge therapy 6
The lack of validated MCTD-specific activity criteria represents a significant gap in the field, requiring clinicians to synthesize multiple organ-specific assessments and borrowed indices from related diseases.